Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study

NCT04334993 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Philadelphia-Negative ALL
High-Risk Cancer

Interventions

DRUG: Blinatumomab

Sponsor

Israeli Medical Association